A simplified and sensitive immunoprecipitation mass spectrometry protocol for the analysis of amyloid-beta peptides in brain tissue.

[1]  J. Wiltfang,et al.  Highly potent soluble amyloid-β seeds in human Alzheimer brain but not cerebrospinal fluid. , 2014, Brain : a journal of neurology.

[2]  K. Blennow,et al.  The amyloid-β degradation pattern in plasma—A possible tool for clinical trials in Alzheimer's disease , 2014, Neuroscience Letters.

[3]  A. Cheema,et al.  The critical need for defining preclinical biomarkers in Alzheimer's disease , 2014, Alzheimer's & Dementia.

[4]  M. Parker,et al.  Do current therapeutic anti-Aβ antibodies for Alzheimer’s disease engage the target? , 2014, Acta Neuropathologica.

[5]  Chi-Yuan Li,et al.  Increased risk of dementia in people with previous exposure to general anesthesia: A nationwide population-based case–control study , 2014, Alzheimer's & Dementia.

[6]  T. Bayer,et al.  N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits , 2013, Acta Neuropathologica.

[7]  K. Blennow,et al.  Pyroglutamate Amyloid β (Aβ) Aggravates Behavioral Deficits in Transgenic Amyloid Mouse Model for Alzheimer Disease , 2012, The Journal of Biological Chemistry.

[8]  G. Slupphaug,et al.  Antibody cross-linking and target elution protocols used for immunoprecipitation significantly modulate signal-to noise ratio in downstream 2D-PAGE analysis , 2011, Proteome Science.

[9]  T. Bayer,et al.  Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. , 2010, The Journal of biological chemistry.

[10]  T. Bayer,et al.  Identification of Low Molecular Weight Pyroglutamate Aβ Oligomers in Alzheimer Disease , 2010, The Journal of Biological Chemistry.

[11]  H. Lashuel,et al.  The Ratio of Monomeric to Aggregated Forms of Aβ40 and Aβ42 Is an Important Determinant of Amyloid-β Aggregation, Fibrillogenesis, and Toxicity* , 2008, Journal of Biological Chemistry.

[12]  Henrik Zetterberg,et al.  Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. , 2007, Journal of proteome research.

[13]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[14]  G. Damonte,et al.  Pyroglutamate‐modified amyloid β‐peptides – AβN3(pE) – strongly affect cultured neuron and astrocyte survival , 2002 .

[15]  Carl W. Cotman,et al.  Amino-terminal Deletions Enhance Aggregation of β-Amyloid Peptides in Vitro(*) , 1995, The Journal of Biological Chemistry.

[16]  P. Lansbury,et al.  The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. , 1993, Biochemistry.

[17]  R. Orlando,et al.  Covalent modification of Alzheimer's amyloid β-peptide in formic acid solutions , 1992 .